Dominik Mumberg

8.4k total citations · 2 hit papers
136 papers, 6.5k citations indexed

About

Dominik Mumberg is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dominik Mumberg has authored 136 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Molecular Biology, 55 papers in Oncology and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dominik Mumberg's work include Radiopharmaceutical Chemistry and Applications (26 papers), Prostate Cancer Treatment and Research (25 papers) and Cancer-related Molecular Pathways (21 papers). Dominik Mumberg is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (26 papers), Prostate Cancer Treatment and Research (25 papers) and Cancer-related Molecular Pathways (21 papers). Dominik Mumberg collaborates with scholars based in Germany, United States and Finland. Dominik Mumberg's co-authors include Rolf Müller, Martin Funk, Karl Ziegelbauer, Gerhard Siemeister, Frances C. Lucibello, Hans Schreiber, Christoph A. Schatz, Antje M. Wengner, Sherry Wanderling and Paul A. Monach and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Dominik Mumberg

131 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds

1995 1.7k citations Dominik Mumberg et al. profile →
Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression

1994 836 citations Dominik Mumberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dominik Mumberg Germany	38	4.2k	1.5k	981	794	684	136	6.5k
Scott B. Ficarro United States	56	7.8k 1.8×	1.7k 1.1×	888 0.9×	585 0.7×	922 1.3×	117	10.3k
Klaus P. Hoeflich United States	36	4.8k 1.1×	2.0k 1.4×	570 0.6×	539 0.7×	572 0.8×	62	6.8k
Stephan Geley Austria	40	3.4k 0.8×	987 0.7×	1.3k 1.4×	271 0.3×	649 0.9×	91	4.9k
Sandeep Burma United States	36	5.0k 1.2×	2.1k 1.4×	400 0.4×	676 0.9×	379 0.6×	82	6.2k
David T. Weaver United States	49	6.5k 1.5×	2.6k 1.8×	747 0.8×	479 0.6×	1.4k 2.0×	150	9.0k
Duane R. Pilch United States	19	7.3k 1.7×	2.1k 1.4×	540 0.6×	547 0.7×	509 0.7×	22	8.5k
Mark Rolfe United States	31	4.6k 1.1×	2.5k 1.7×	1.2k 1.2×	437 0.6×	407 0.6×	55	6.0k
Akihiro Kurimasa Japan	36	4.8k 1.1×	1.6k 1.1×	418 0.4×	396 0.5×	399 0.6×	90	6.3k
Sara Lavi Israel	38	4.4k 1.0×	3.2k 2.2×	583 0.6×	493 0.6×	582 0.9×	72	6.7k
Adly Yacoub United States	46	3.5k 0.8×	2.0k 1.4×	563 0.6×	572 0.7×	678 1.0×	93	5.6k

Countries citing papers authored by Dominik Mumberg

Since Specialization

Citations

This map shows the geographic impact of Dominik Mumberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominik Mumberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominik Mumberg more than expected).

Fields of papers citing papers by Dominik Mumberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dominik Mumberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominik Mumberg. The network helps show where Dominik Mumberg may publish in the future.

Co-authorship network of co-authors of Dominik Mumberg

This figure shows the co-authorship network connecting the top 25 collaborators of Dominik Mumberg. A scholar is included among the top collaborators of Dominik Mumberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominik Mumberg. Dominik Mumberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sugawara, Tatsuo, Ekaterina Nevedomskaya, Simon Heller, et al.. (2024). Dual targeting of the androgen receptor and PI3K / AKT / mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Molecular Oncology. 18(3). 726–742. 13 indexed citations

Böhnke, Niels, Bård Indrevoll, Stefanie Hammer, et al.. (2023). Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models. European Journal of Nuclear Medicine and Molecular Imaging. 51(3). 669–680. 9 indexed citations

Suominen, Mari I., Matias Knuuttila, Birgitta Sjöholm, et al.. (2023). Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model. Cancers. 15(16). 4115–4115. 2 indexed citations

Regan, Joseph L., Dirk Schumacher, Andreas Steffen, et al.. (2022). Identification of a neural development gene expression signature in colon cancer stem cells reveals a role for EGR2 in tumorigenesis. iScience. 25(7). 104498–104498. 17 indexed citations

Lejeune, Pascale, Véronique Cruciani, Andreas Schlicker, et al.. (2021). Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy. Journal for ImmunoTherapy of Cancer. 9(10). e002387–e002387. 36 indexed citations

Regan, Joseph L., Dirk Schumacher, Andreas Steffen, et al.. (2021). RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence. iScience. 24(6). 102618–102618. 13 indexed citations

Wengner, Antje M., Gerhard Siemeister, Ulrich Lücking, et al.. (2019). The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models. Molecular Cancer Therapeutics. 19(1). 26–38. 145 indexed citations

Hammer, Stefanie, Urs B. Hagemann, Sabine Zitzmann-Kolbe, et al.. (2019). Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clinical Cancer Research. 26(8). 1985–1996. 94 indexed citations

Hagemann, Urs B., Christine Ellingsen, Joachim Schuhmacher, et al.. (2019). Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clinical Cancer Research. 25(15). 4723–4734. 86 indexed citations

10.

Karlsson, Jenny, Christine Ellingsen, Véronique Cruciani, et al.. (2019). Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model. Pharmaceuticals. 12(4). 155–155. 29 indexed citations

11.

Siemeister, Gerhard, Anne Mengel, Amaury E. Fernández‐Montalván, et al.. (2018). Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo. Clinical Cancer Research. 25(4). 1404–1414. 53 indexed citations

12.

Suominen, Mari I., Jukka P. Rissanen, Jukka Morko, et al.. (2017). Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clinical Cancer Research. 23(15). 4335–4346. 137 indexed citations

13.

Wengner, Antje M., Gerhard Siemeister, Marcus Koppitz, et al.. (2016). Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. Molecular Cancer Therapeutics. 15(4). 583–592. 85 indexed citations

14.

Huynh, Hung, Richard Ong, Florian Puehler, et al.. (2016). Abstract 2276: Sorafenib/Refametinib potently inhibits Wnt/β-catenin in vitro and patient-derived xenograft models of human hepatocellular carcinoma. Cancer Research. 76(14_Supplement). 2276–2276. 2 indexed citations

15.

Scholz, Arne, Gerhard Siemeister, Philip Lienau, et al.. (2015). Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. Cancer Research. 75(15_Supplement). DDT02–2. 8 indexed citations

16.

Schmieder, Roberta, Florian Puehler, Roland Neuhaus, et al.. (2013). Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma. Neoplasia. 15(10). 1161–IN24. 51 indexed citations

17.

Liu, Ningshu, Bruce R. Rowley, Cathy Bull, et al.. (2013). BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models. Molecular Cancer Therapeutics. 12(11). 2319–2330. 206 indexed citations

18.

Siemeister, Gerhard, Ulrich Lücking, Antje M. Wengner, et al.. (2012). BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application. Molecular Cancer Therapeutics. 11(10). 2265–2273. 131 indexed citations

19.

Wellenreuther, Ruth, Dietrich Keppler, Dominik Mumberg, Karl Ziegelbauer, & Monika Lessl. (2012). Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. Drug Discovery Today. 17(21-22). 1242–1248. 15 indexed citations

20.

Wiestler, OD, Bernard Haendler, & Dominik Mumberg. (2007). Cancer stem cells : Novel concepts and prospects for tumor therapy. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact